Download PDF
Thromb Haemost
DOI: 10.1055/a-2225-5428
Stroke, Systemic or Venous Thromboembolism

Risk of Depression after Venous Thromboembolism in Patients with Hematological Cancer: A Population-Based Cohort Study

Daniel Steiner 
1   Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
2   Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
,
Erzsébet Horváth-Puhó
2   Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
,
Helle Jørgensen
3   Department of Clinical Medicine, Thrombosis Research Center (TREC), UiT–The Arctic University of Norway, Tromsø, Norway
,
Kristina Laugesen
2   Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
4   Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
,
Cihan Ay
1   Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Henrik Toft Sørensen
2   Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
› Author Affiliations Funding Sources The work was supported by the Independent Research Fund Denmark (record no. 3101–00102B) and the Karen Elise Jensen's Foundation.
› Further Information
    Permissions and Reprints


Abstract

Background Venous thromboembolism (VTE) may complicate the clinical course of cancer patients and add to their psychological burden.

Objectives We aimed to investigate the association between VTE and risk of subsequent depression in patients with hematological cancer.

Patients and Methods We conducted a population-based cohort study using Danish national health registries. Between 1995 and 2020, we identified 1,190 patients with hematological cancer and incident VTE diagnosed within 6 months before to 1 year after cancer diagnosis. A comparison cohort of patients with hematological cancer without VTE (n = 5,325) was matched by sex, year of birth, cancer type, and year of cancer diagnosis. Patients were followed until diagnosis of depression, emigration, death, study end (2021), or for a maximum of 3 years. Depression was defined as hospital discharge diagnosis of depression or ≥1 prescription for antidepressants. Absolute risks of depression were computed with cumulative incidence functions, treating death as competing event. Hazard ratios (HRs) with 95% confidence intervals (CIs) were computed using Cox proportional hazards regression models, adjusting for comorbidities.

Results Depression was observed in 158 hematological cancer patients with and 585 without VTE. The 3-year absolute risks of depression were 13.3% (95% CI: 11.5–15.3%) in the VTE cancer cohort and 11.1% (95% CI: 10.3–12.0%) in the comparison cancer cohort, corresponding to a risk difference of 2.2% (95% CI: -1.8–6.5%). VTE was associated with an increased relative risk of depression (adjusted HR: 1.56, 95% CI: 1.28–1.90).

Conclusion VTE was associated with an elevated risk of subsequent depression in patients with hematological cancer.

Keywords

epidemiology - hematological cancer - neoplasms - disorders - venous thromboembolism

Note

The Department of Clinical Epidemiology receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University (none of these studies has any relation to the present study).


Data Availability Statement

Individual-level patient data from this study cannot be made available to other researchers due to Danish privacy law, but can be obtained from the Danish Health Data Agency.


Authors' Contribution

D.S., E.H.-P., H.J., C.A., and H.T.S. contributed to study concept and design. E.H.-P. performed the statistical analysis. All authors contributed to interpretation of the data. D.S. drafted the manuscript. All authors critically revised the manuscript and approved the final version before submission.


Supplementary Material



Publication History

Received: 06 October 2023

Accepted: 08 December 2023

Accepted Manuscript online:
11 December 2023

Article published online:
18 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    Google Scholar
  • 2 Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J 2020; 10 (05) 56
    CrossrefPubMedGoogle Scholar
  • 3 Adelborg K, Corraini P, Darvalics B. et al. Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study. J Thromb Haemost 2019; 17 (08) 1305-1318
    CrossrefPubMedGoogle Scholar
  • 4 Mitchell AJ, Chan M, Bhatti H. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011; 12 (02) 160-174
    CrossrefPubMedGoogle Scholar
  • 5 Boyes AW, Girgis A, D'Este C, Zucca AC. Flourishing or floundering? Prevalence and correlates of anxiety and depression among a population-based sample of adult cancer survivors 6months after diagnosis. J Affect Disord 2011; 135 (1–3): 184-192
    CrossrefPubMedGoogle Scholar
  • 6 Raskob GE, Angchaisuksiri P, Blanco AN. et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34 (11) 2363-2371
    CrossrefPubMedGoogle Scholar
  • 7 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
    CrossrefPubMedGoogle Scholar
  • 8 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Noble S, Prout H, Nelson A. Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study. Patient Prefer Adherence 2015; 9 (09) 337-345
    CrossrefPubMedGoogle Scholar
  • 10 Noble SI, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 2005; 19 (03) 197-201
    CrossrefPubMedGoogle Scholar
  • 11 Mockler A, O'Brien B, Emed J, Ciccotosto G. The experience of patients with cancer who develop venous thromboembolism: an exploratory study. Oncol Nurs Forum 2012; 39 (03) E233-E240
    CrossrefPubMedGoogle Scholar
  • 12 Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence 2014; 8 (08) 453-461
    PubMedGoogle Scholar
  • 13 Font C, Nelson A, Garcia-Fernandez T, Prout H, Gee P, Noble S. Patients' experience of living with cancer-associated thrombosis in Spain (PELICANOS). Support Care Cancer 2018; 26 (09) 3233-3239
    CrossrefPubMedGoogle Scholar
  • 14 Noble S, Nelson A, Scott J. et al. Patient Experience of Living With Cancer-Associated Thrombosis in Canada (PELICANADA). Res Pract Thromb Haemost 2019; 4 (01) 154-160
    CrossrefPubMedGoogle Scholar
  • 15 Benelhaj NB, Hutchinson A, Maraveyas AM, Seymour JD, Ilyas MW, Johnson MJ. Cancer patients' experiences of living with venous thromboembolism: a systematic review and qualitative thematic synthesis. Palliat Med 2018; 32 (05) 1010-1020
    CrossrefPubMedGoogle Scholar
  • 16 Jørgensen H, Horváth-Puhó E, Laugesen K, Brækkan S, Hansen J-B, Sørensen HT. Venous thromboembolism and risk of depression: a population-based cohort study. J Thromb Haemost 2023; 21 (04) 953-962
    CrossrefPubMedGoogle Scholar
  • 17 Tzeng N-S, Chung C-H, Chang S-Y. et al. Risk of psychiatric disorders in pulmonary embolism: a nationwide cohort study. J Investig Med 2019; 67 (06) 977-986
    CrossrefPubMedGoogle Scholar
  • 18 The Lancet Haematology. Thrombosis and mental health. Lancet Haematol 2022; 9 (08) e547
    CrossrefPubMedGoogle Scholar
  • 19 Schmidt M, Schmidt SAJ, Adelborg K. et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 2019; 11 (11) 563-591
    CrossrefPubMedGoogle Scholar
  • 20 Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29 (08) 541-549
    CrossrefPubMedGoogle Scholar
  • 21 Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry–history, content, quality and use. Dan Med Bull 1997; 44 (05) 535-539
    PubMedGoogle Scholar
  • 22 Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39 (07) 42-45
    CrossrefPubMedGoogle Scholar
  • 23 Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health 2011; 39 (07) 54-57
    CrossrefPubMedGoogle Scholar
  • 24 Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449-490
    CrossrefPubMedGoogle Scholar
  • 25 Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39 (07) 38-41
    CrossrefPubMedGoogle Scholar
  • 26 Sundbøll J, Adelborg K, Munch T. et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 2016; 6 (11) e012832
    CrossrefPubMedGoogle Scholar
  • 27 Galsklint J, Kold S, Kristensen SR, Severinsen MT, Gade IL. Validation of postsurgical venous thromboembolism diagnoses of patients undergoing lower limb orthopedic surgery in the Danish National Patient Registry. Clin Epidemiol 2022; 14: 191-199
    CrossrefPubMedGoogle Scholar
  • 28 Heide-Jørgensen U, Adelborg K, Kahlert J, Sørensen HT, Pedersen L. Sampling strategies for selecting general population comparison cohorts. Clin Epidemiol 2018; 10: 1325-1337
    CrossrefPubMedGoogle Scholar
  • 29 Bock C, Bukh JD, Vinberg M, Gether U, Kessing LV. Validity of the diagnosis of a single depressive episode in a case register. Clin Pract Epidemiol Ment Health 2009; 5 (01) 4
    CrossrefPubMedGoogle Scholar
  • 30 Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170 (02) 244-256
    CrossrefPubMedGoogle Scholar
  • 31 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370 (9596) 1453-1457
    CrossrefPubMedGoogle Scholar
  • 32 Hou J-Z, Ye JC, Pu JJ. et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol 2021; 14 (01) 66
    CrossrefPubMedGoogle Scholar
  • 33 Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev 2019; 33: 24-32
    CrossrefPubMedGoogle Scholar
  • 34 Lund JL, Østgård LS, Prandoni P, Sørensen HT, de Nully Brown P. Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. Thromb Res 2015; 136 (05) 917-923
    CrossrefPubMedGoogle Scholar
  • 35 McGee G, Haneuse S, Coull BA, Weisskopf MG, Rotem RS. On the nature of informative presence bias in analyses of electronic health records. Epidemiology 2022; 33 (01) 105-113
    CrossrefPubMedGoogle Scholar